Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, ...

Crispr Therapeutics said it is partnering with Sirius Therapeutics to develop and commercialize SRSD107, a small interfering RNA therapy to treat thromboembolic disorders. Under the agreement, Crispr ...

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR ...

The Cambridge biotech's wild ambitions for a powerful gene editing technology sank as the biotech market slumped.

One of them is CRISPR Therapeutics ( CRSP 1.99%). It has an approved gene-editing therapy, but investors haven't been buying ...

In a world first, scientists used CRISPR to fix a baby's unique genetic mutation. The report offers hope for personalized ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ...

Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from ...

CRISPR Therapeutics has an approved gene-therapy treatment still in its early growth stages. One of them is CRISPR Therapeutics (NASDAQ: CRSP). Its financials haven't been looking all that ...

Explore CRISPR Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CRSP. CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be ...